1720 Participants Needed

Firehawk Stent for Coronary Artery Disease

(TARGET-IV_NA Trial)

Recruiting at 56 trial locations
MZ
Overseen ByMing Zheng
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Shanghai MicroPort Medical (Group) Co., Ltd.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial is testing a new type of stent that releases a drug to keep heart arteries open in patients with certain types of heart disease. The goal is to see if it works as well as current treatments. Drug-eluting stents, which release drugs to prevent artery blockage, have shown promising results and are a major focus in cardiovascular medicine.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, if you have an allergy to any trial-required medications or are on chronic oral anticoagulant treatment, you may not be eligible to participate.

Is the Firehawk Stent safe for use in humans?

The Firehawk Stent has been shown to have a safety profile comparable to the XIENCE stent, with no significant differences in major adverse events over a 5-year period. It is designed to reduce inflammation and hypersensitivity reactions, and no cases of stent thrombosis were reported in the Firehawk group during the 5-year follow-up.12345

How is the Firehawk stent treatment different from other treatments for coronary artery disease?

The Firehawk stent is unique because it uses a biodegradable polymer that releases sirolimus, a drug that helps prevent artery blockage, from grooves on the stent's surface. This design aims to reduce long-term complications compared to traditional stents that use a permanent polymer.23467

What data supports the effectiveness of the Firehawk stent treatment for coronary artery disease?

Research shows that the Firehawk stent is as effective and safe as the Xience V stent for treating coronary artery disease, with similar rates of complications and no cases of stent blockage over five years.23468

Who Is on the Research Team?

ML

Martin Leon

Principal Investigator

Columbia University

Are You a Good Fit for This Trial?

Adults with coronary artery disease who need a stent and can follow the trial's procedures. They should have certain types of heart conditions like angina or recent heart attacks, but not be in immediate critical condition (like shock) or have had a very recent stent procedure. People with severe heart failure, planned surgeries, allergies to trial materials, other serious illnesses, or on certain medications cannot join.

Inclusion Criteria

My heart condition involves complex issues like calcified or twisted arteries.
It is likely that the study device can be safely placed in the target area of the heart.
Patient is willing to comply with all protocol-required follow-up evaluations
See 4 more

Exclusion Criteria

My heart condition requires two stents due to a bifurcation lesion.
My kidney function, measured by creatinine clearance, is low.
I am on immunosuppressive therapy or have an autoimmune disease.
See 27 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants are randomized to receive either the Firehawk® rapamycin eluting stent or a 2nd generation DES

Procedure day
1 visit (in-person)

Follow-up

Clinical follow-up to monitor safety and effectiveness, including angiographic and OCT assessments for sub-study participants

5 years
Visits at 30 days, 6 months, 1, 2, 3, 4, and 5 years

Angiographic and OCT Sub-study

Angiographic follow-up at 13 months for first 200 patients, with OCT for first 50 of these patients

13 months
1 visit (in-person)

What Are the Treatments Tested in This Trial?

Interventions

  • 2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)
  • Firehawk Stent
Trial Overview The trial is testing if the Firehawk rapamycin eluting stent system is as good as current second-generation drug-eluting stents for treating people with ischemic heart disease. It involves patients whose coronary arteries are of specific sizes and who may have complex lesions.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: Firehawk groupExperimental Treatment1 Intervention
Participants implant Firehawk stent(s)
Group II: 2nd generation DESActive Control1 Intervention
Participants implant Everolimus eluting stents (Xience family - Abbott Vascular, Promus family- Boston Scientific, Synergy - Boston Scientific), or Zotarolimus eluting stents (Resolute/Onyx family and Endeavor- Medtronic), or Sirolimus eluting stents (Orsiro- Biotronik)

Find a Clinic Near You

Who Is Running the Clinical Trial?

Shanghai MicroPort Medical (Group) Co., Ltd.

Lead Sponsor

Trials
24
Recruited
19,600+

Citations

A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial. [2022]
[Long term safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of coronary de novo lesions]. [2018]
2-Year Clinical Outcomes of an Abluminal Groove-Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent. [2020]
Clinical outcomes of complex lesions treated with an abluminal groove-filled biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent. [2021]
Resolute Italian study in all comers: immediate and one-year outcomes. [2014]
The Firehawk Stent: A Review of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent. [2021]
Device profile of the XIENCE V and XIENCE Sierra stents for the treatment of coronary artery disease: an overview of safety and efficacy. [2020]
Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial. [2018]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security